FDA issues warning about medications containing oxybutynin
July 15, 2011
Some of medications (Ditropan®, Ditropan XL®, Gelnique® gel, Oxytrol® transdermal patch) used to treat urinary problems in people with MS contain oxybutynin. The FDA has added a warning to the labeling of these medications stating that angioedema (a swelling similar to hives that occurs under the skin) of the face, lips, tongue and/or larynx has been reported with oxybutynin taken orally. In some cases, angioedema occurred after the first dose; in other cases it occurred with later doses. The swelling was severe enough in some individuals to interfere with breathing and required hospitalization and emergency treatment. Although this reaction appears to be relatively rare, given the many years that oxybutynin has been used safely and successfully by people with MS and others, any person taking a medication containing oxybutynin who experiences swelling of the tongue or throat or difficulty breathing should stop the medication and seek immediate medical attention. Individuals who have questions or concerns about this medication should discuss them with their physician.
Read more about bladder dysfunction in MS.
The National MS Society, founded in 1946, funds cutting-edge research, drives change through advocacy, and provides programs and services to help people affected by MS live their best lives. Connect to learn more and get involved: nationalMSsociety.org, Facebook, Twitter, Instagram, YouTube or 1-800-344-4867.